# A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

> **NCT00751842** · PHASE3 · TERMINATED · sponsor: **Diamyd Therapeutics AB** · enrollment: 331 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** rhGAD65
- **DRUG:** rhGAD65
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00751842
- **Lead sponsor:** Diamyd Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2012-03
- **Final completion:** 2012-07
- **Target enrollment:** 331 (ACTUAL)
- **Why stopped:** Based on other clinical trial results it was unlikely the study would meet the efficacy endpoints
- **Last updated:** 2012-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00751842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00751842, "A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00751842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*